Company Overview and News
KUALA LUMPUR (Oct 2): AllianceDBS Research said Rev Asia Bhd (Rev) had on Oct 1 crossed over the 33 sen hurdle to reach a high of 34.5 sen before settling at 33.5 sen (up 1.5 sen or 4.68%).
KUALA LUMPUR (Sept 25): Media Prima Bhd's wholly-owned subsidiary Rev Asia Holdings Sdn Bhd has entered into an agreement with US-based digital media company Ziff Davis LLC to operate Mashable Southeast Asia (sea.mashable.com) for audiences across Indonesia, Malaysia, the Philippines and Singapore.
4502 MIAHF 0173
Media Prima Bhd (Sept 3, 45 sen) Maintain neutral with a higher target price of 49 sen: Media Prima Bhd’s second quarter of the financial year ended June 30, 2018 (2QFY18) revenue grew 4.1% year-on-year (y-o-y), mainly driven by higher digital advertising and home shopping revenue. The group reduced its reliance on traditional businesses from 88% in the first half of FY17 (1HFY17) to 77% in 1HFY18.
4502 MIAHF 0173
KUALA LUMPUR (Aug 15): theedgemarkets.com highlighted six stocks with momentum at Bursa Malaysia’s afternoon market close today. Two stocks displayed positive momentum and four showed negative momentum.
0173 BSMAF 1818
There are many others that are unable to meet their obligations and they were all previously under Ministry of Finance Inc (MoF). Towards this end, the government has now placed many of the funds under the Energy, Science, Technology, Environment and Climate Change Ministry, led by Yeo Bee Yin(pic).
0025 0173 0151
KUALA LUMPUR (July 30): Based on corporate announcements and news flow today, companies in focus on Tuesday (July 31) may include: Top Glove Corp Bhd, JAKS Resources Bhd, Star Media Group Bhd, Malaysia Building Society Bhd, Barakah Offshore Petroleum Bhd, Handal Resources Bhd, Fima Corp Bhd, Datasonic Group Bhd, New Hoong Fatt Holdings Bhd, Rev Asia Bhd and Tadmax Resources Bhd
6084 7251 7060 7113 TPGVF 1171 0173 7253 4022 TGLVY 5216 4723 WWDH
A less frequently talked about component of the Digital Free Trade Zone is KL Internet City (KLIC), a RM5 billion development meant to be a digital hub for global technology companies in Bandar Malaysia. However, due to uncertainties over the new government’s plans for Bandar Malaysia, KLIC’s master developer, Catcha Group Pte Ltd, has been looking for an alternative site.
4502 MIAHF 0173
REV Asia Bhd is seeing some upside momentum even as the share price challenges the immediate resistance level in a possible breakout attempt. At the day's high of 31 sen, the stock has passed the 30 sen hurdle, and met with the 100-day simple moving average (SMA). Should the counter break free of these obstacles, it would move out of consolidation mode, which it has been trapped in since April an move higher towards an ensuing resistance of 36 sen.
Media Prima Bhd (June 12, 53 sen) Upgrade to neutral with a higher target price of 42 sen: Media Prima Bhd narrowed its loss by 43.3% in the recent quarter. Quarterly revenue increased for the first time in first quarter of financial year 2018 (1QFY18) (+3.1% year-on-year [y-o-y]) since 3QFY13 as the digital and commerce revenue growth outpaced the drop in TV revenue. The decline in print revenue also narrowed to only 0.
4502 MIAHF 0173
THE Malaysian Digital Association (MDA) has re-elected Serm Teck Choon, Malaysia country head of CtrlShift, and Nick Drew, head of agency of Google Malaysia, as the president and vice-president at the association’s recent AGM.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...